Cardio Axis
Cardio Axis
Cardio Axis
Company Overview - Cardio Axis is a company based in India that specializes in the field of cardiovascular
health. They focus on developing and providing advanced technologies and solutions for diagnosing and
managing cardiovascular diseases. Their products and services typically include diagnostic tools, medical
devices, and potentially software solutions designed to improve cardiovascular care.
Incorporation - Cardio Axis was incorporated in 2016. The company focuses on advancing cardiovascular health
through innovative technologies and solutions. If you’re looking for more detailed information about their
history, products, or recent updates, their official website or press releases would be good sources to check.
Man behind the company - Dr. Rakesh H. Dube is indeed associated with Cardio Axis. He is the founder and
CEO of the company. Dr. Dube has a background in medicine and a strong focus on cardiovascular health,
driving the company's mission to innovate and provide advanced solutions in this field.
Products
1. Drug-Eluting Stents (DES) - Drug-eluting stents are used to keep arteries open after an angioplasty
procedure. They are coated with a medication that helps prevent the artery from re-narrowing.
2. PTCA Balloons - These balloons are used during percutaneous transluminal coronary angioplasty (PTCA)
procedures to dilate narrowed coronary arteries.
3. Accessories - A range of support tools and devices used in conjunction with stents and balloons.
4. Drug-Eluting Balloons (DEB) - Similar to drug-eluting stents, drug-eluting balloons deliver medication to the
artery wall while expanding it to treat blockages.
5. Structural Heart Devices - These products are designed to address structural heart diseases and
abnormalities through minimally invasive procedures.
Awards
1. Advanced cardiovascular solutions with pioneering products like the Everton Everolimus Eluting Stent
and Oasis Drug Eluting Balloon.
2. Leads in developing groundbreaking technologies, including Transcatheter Aortic Valve Implantation
(TAVI) systems.
3. Collaborates with top hospitals and global entities to enhance market presence and reach.
4. Committed to extending device life and improving patient outcomes with advanced, patented
technologies.
Manipal Hospitals
AMRI Hospitals
Fortis Hospitals
Lions Hospitals
IVY Hospitals
Market and Industry
Cardio Axis's Total Addressable Market (TAM) includes the expanding coronary stent market and the rapidly
growing transcatheter aortic valve (TAV) market. In India, PTCA procedures are increasing by 16% annually,
offering significant opportunities for Cardio Axis amid strong domestic competition. Globally, the TAV market,
valued at USD 4.5 billion in 2022, is projected to reach USD 7.1 billion by 2026 with a 12.2% CAGR and is
expected to grow to USD 25.4 billion by 2033 at a 14.8% CAGR. In India, the TAV market is growing at 9%
annually with 236 centers performing about 2,445 procedures in 2023. The average price for a valve is
projected to be INR 5.5 lakhs by 2026, with costs ranging from INR 75,000 to INR 1 lakh, highlighting a
competitive landscape with both international and local players..
SWOT Analysis
Strengths Weakness
Proposed Management
Mr. Phillip Winters Ohle hale Interventional Cardiology Clinical and Marketing Expert, CardioAxis
Experience of 15 years Corporation (TAVR Project)
Dr. WON-KEUN KIM MD, Ph.D MD, Ph.D. Expert in Structural Heart Projects, CardioAxis
Corporation (TAVI Valve Development)
Dr. Ashok Seth Padma Shri, Padma Chairman & Director, Fortis Escorts Heart Institute,
Vibhushan, Chairman & Delhi
Professor
Product Portfolio
Everton Drug Eluting Stent Everolimus Eluting Coronary Stent System CardioAxis Corporation
Pvt Ltd
Excalibur Legend Drug Everolimus Eluting Coronary Stent System with CardioAxis Corporation
Eluting Stent unique features Pvt Ltd
Oasis Drug Eluting Balloon Drug Eluting Balloon used for coronary CardioAxis Corporation
interventions Pvt Ltd
Sirolimus Coated Balloon Used for the treatment of ISR and Coronary CardioAxis Corporation
Artery Disease Pvt Ltd
Products to be launched
APT Medical, China Exclusive Distribution Rights for India CardioAxis Corporation Pvt Ltd
Note: APT Medical, China has conducted successful clinical trials for their products, including the Spherical Tip
NC Balloon Conqueror, with a 98.9% success rate.
Filled Patents
1. Puncture Needle
2. PTCA Balloon Inflation Device
3. PTCA Y-Connector Kit
4. PTFE Coated Angiography Wire
5. Manifolds
6. Pressure Lines
7. Guide Extension Catheter
8. Microcatheter
9. High Pressure NC Balloon
10. PTCA Guidewires
Financials
The company is looking forward to raise INR 193 Cr towards capital over the period of next 30 months.
3 First in Man – 150 Patients (Min 75 Patients in Euro 2026-27 Q3 onwards 77,00,00,000
Territory)
Early Feasibility Study
CE Study and Certifications
TOTAL 193,00,00,000